Opsynvi
Payments companies reported to CMS as associated with Opsynvi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Opsynvi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Opsynvi
These are the largest totals companies reported as associated with Opsynvi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Neal Chaisson | Cleveland, OH | Critical Care Medicine (Internal Medicine) | $22,296.20 |
| Jean Elwing | Cincinnati, OH | Pulmonary Disease | $5,967.54 |
| Marc Simon | San Francisco, CA | Advanced Heart Failure and Transplant Cardiology | $5,195.21 |
| Timothy Fernandes | La Jolla, CA | Pulmonary Disease | $4,350.00 |
| Jonathan Moore | Phoenix, AZ | Pulmonary Disease | $3,629.14 |
| Mrinalini Krishnan | Washington, DC | Advanced Heart Failure and Transplant Cardiology | $3,354.03 |
| Michael Cuttica | Chicago, IL | Critical Care Medicine (Internal Medicine) | $3,330.00 |
| Melisa Wilson | Orlando, FL | Acute Care (Nurse Practitioner) | $3,250.83 |
| Roberto Swazo | Orlando, FL | Pulmonary Disease | $2,640.00 |
| Kimberly Thompson | Rochester, MN | Nurse Practitioner | $1,500.00 |
Prescribed Opsynvi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.